KWM
IBB icon

Kingsview Wealth Management’s iShares Biotechnology ETF IBB Stock Holding History

Kingsview Wealth Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-200
Closed -$26K – 930
2021
Q4 		$26K Buy
+200
New +$31K ﹤0.01% 924
2021
Q2 		– Sell
-400
Closed -$1K – 953
2021
Q1 		$1K Buy
+400
New +$63.5K ﹤0.01% 848
2017
Q2 		– Sell
-3,300
Closed -$4K – 373
2017
Q1 		$4K Buy
+3,300
New +$316K ﹤0.01% 262

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Kingsview Wealth Management's IBB Position: Q1 2026 in Review

Kingsview Wealth Management increased its iShares Biotechnology ETF (IBB) stake by 13% in Q1 2026, buying an estimated $69.4K and bringing the position to 3,641 shares worth $615K. The position accounts for 0.01% of the portfolio, ranked #830.

Kingsview Wealth Management first reported a position in IBB in Q1 2017 and has held it in 37 quarters since. The position peaked at $4.24M in Q4 2024. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

  • Kingsview Wealth Management held 3,641 shares of iShares Biotechnology ETF worth $615K as of Q1 2026.
  • Kingsview Wealth Management bought 406 iShares Biotechnology ETF shares in Q1 2026, an estimated $69.4K.
  • iShares Biotechnology ETF made up 0.01% of Kingsview Wealth Management's portfolio in Q1 2026, its #830 holding.
  • Kingsview Wealth Management first reported a position in iShares Biotechnology ETF in Q1 2017 and has held it in 37 quarters since.
  • Kingsview Wealth Management's iShares Biotechnology ETF position peaked at $4.24M in Q4 2024.
  • 917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Kingsview Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.